why choose us

First received: April 15, 2026

Clinical Trial: Rivastigmine for the Treatment of Hypoactive Anticholinergic Delirium and CNS Depression Associated Mainly With Clozapine Poisoning.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Anticholinergic Delirium

Study Type: INTERVENTIONAL


Official Title: Efficacy of Rivastigmine in the Management of Toxic Anticholinergic Delirium: A Prospective Study at Alexandria Poison Center

Brief Summary: This study aims to evaluate the clinical efficacy of rivastigmine in reversing the full spectrum of toxic anticholinergic delirium, with a specific focus on hypoactive delirium and CNS depression.These presentations were predominantly associated with clozapine toxicity, accounting for 90% of the study population.Additionally, the research investigates the safety and efficacy of rivastigmine in reversing CNS depression caused by Tricyclic Antidepressants (TCAs), challenging traditional concerns regarding the use of…

Read more